S1 fast scan, addresses this issue: probuphine approved on non-inferiority to sublingual, yet poses additional costs of administration; not surprising uphill adoption; Apple T has sunk > 200 million in Braeburn & they need > cash: “Our failure to raise capital as and when needed would have a material adverse impact on our financial condition and our ability to pursue our business strategies, including but not limited to insolvency” (p89).. "if we are unable to obtain additional financing, future operations would need to be scaled back or discontinued. Accordingly, there is substantial doubt regarding our ability to continue as a going concern" (p 93) ; Sheldon may have abandoned ship… Braeburn’s pipeline currently is very risky against strong well-capitalized competitors.. . Risperidone implants = foolish venture IMHO… psychiatrists in prison have a tough time getting consent from inmates for Invega monthly shot… can’t see them even trying long term implant.. most patients stop taking these meds due to side effects they do not like… as far as involuntary medication, psychiatrists have to get a court order for a limited time to administer involuntary medication AND must demonstrate PT is danger to self, danger to others or gravely disabled to get the court’s OK.. makes probuphine look like a cake walk… so.. I’m keeping my small stake as an option for a possible buyout by stronger competitor as neither Braeburn or TTNP have the resources to make a success of this, even in the midst of this epidemic.. scenario: either INVVY or ALKS buys TTNP & the license from Apple T (both can use probuphine right now) and then both merge for a powerhouse to address the opioid conflagration .. probuphine in the right hands is a valuable treatment option to a practitioner's armamentarium for opioid treatment ..
